This content was published in 2014. We do not recommend that you take any clinical decisions based on this information without first ensuring you have checked the latest guidance.
The prevalence of dementia is increasing with age and the social, carer and economic effects of this are now being recognised worldwide. Alzheimer’s disease is the most common type of dementia and is characterised by atrophy and loss of neurones in the areas of the brain that are associated with memory and cognition. Symptoms of dementia include memory loss, disorientation and losing the ability to perform core activities of daily living.
The diagnosis of dementia is reached by the exclusion of other conditions, since there are currently no specific diagnostic investigations available. Although some risk factors are fixed, others may be modifiable.Since these modifiable risks are also implicated in other conditions such as cardiovascular disease and stroke, pharmacists can encourage their reduction as part of healthy lifestyle advice.
Dementia is a common condition. The average time from diagnosis to death is eight to 10 years.However, it may be many years from the time the first symptoms are noticed to the actual diagnosis.Dementia does not just affect memory; it has an impact on function, speech, swallowing, mobility and continence, which worsen as the condition progresses. The resulting care needs place huge social and economic costs on individuals and society.At a dementia summit held in London in December2013, leaders from the G8 countries — which include theUK and the US — recognised that 36 million people worldwide have the disease and predicted this number to double every two decades. As well as agreeing to increase the amount spent on dementia research significantly, with the aim to identify a cure or a disease-modifying therapy by 2025, the G8countries agreed the development of an international action plan for research, which will include the sharing of information and data.
In 2010, the total estimated worldwide cost of dementia was $604bn. This was around 1% of the world’s gross domestic product, varying from 0.24% in low income countries to 1.24% in high income countries. If dementia care were a country, it would have the world’s 18th largest economy. In the UK, dementia costs were approximately £23bn per year by 2012. This did not include the cost borne by carers, which was estimated to be around £8bn.
By 2012, almost 800,000 people in the UK were living with dementia, equating to just over 1% of the population, with approximately 17,000 of patients being under the age of 65 years. This total is set to rise as the population ages and has been estimated to reach one million by 2021 and 1.7million by 2051. Nevertheless, a recent study in the UK indicates that the prevalence of dementia is falling. Figure 1 shows 2012 UK dementia prevalence by age group. Two-thirds of people with dementia live in their own homes while the other third live in care homes. Some 64% of care home residents have dementia and around a quarter of hospital beds are occupied by people with some form of dementia.
Clinical features and diagnosis
The International Classification of Diseases 10th revision(ICD-10) defines dementia as “a syndrome due to disease of the brain, usually of a chronic or progressive nature, in which there is a disturbance of multiple higher cortical functions, including memory, thinking, orientation, comprehension, calculation, learning capability, language and judgement. Consciousness is not clouded. The impairments of cognitive function are commonly accompanied, and occasionally preceded, by deterioration in emotional control, social behaviour or motivation.”
The symptoms of dementia can be divided into three stages of severity (see Box 1). It should be noted that dementia involves more than forgetting; there must be at least two losses of higher functions and these must be affecting activities of daily living. Behavioural and psychological symptoms of dementia(BPSD) occur in 90% of people with the condition at some point in their illness. BPSD is an umbrella term describing non-cognitive symptoms, such as verbal and physical aggression, agitation, psychotic symptoms(hallucinations and delusions), sleep disturbances and wandering.
A diagnosis of dementia is usually made by taking an accurate history from the patient and his or her carer, which can be supported with cognitive testing.According to the National Institute for Health andCare Excellence,9clinical cognitive assessment for people with suspected dementia should include examination of attention and concentration, orientation, short and long-term memory, language and executive function. Formal cognitive testing using a standardised instrument — such as the “mini mental state examination” (MMSE) —should take place as part of this assessment. Alternative tools include the “six-item cognitive impairment test”(6-CIT), the “general practitioner assessment of cognition” (GPCOG) and the “seven-minute screen”. NICE says that clinicians who interpret cognitive testing scores should take account of other factors that can affect performance, including: educational level and skills, language and previous level of functioning, as well as any sensory impairments, mental illness or physical or neurological problems. Despite advances in radiology and cerebrospinal fluid testing, there are no specific investigations that can be used to make a diagnosis of dementia. NICE recommends that a structural scan, using magnetic resonance imaging (MRI)or computed tomography, is taken to exclude space-occupying lesions and normal pressure hydrocephalus. Blood tests can be carried out to exclude hypothyroidism, vitamin B12deficiency and more common comorbid conditions, such as diabetes or anaemia.
Figure 2 shows the proportions of people in the UK with the various forms of dementia, described in more detail below.
Alzheimer’s disease Alzheimer’s disease is the most common type of dementia. It is characterised by atrophy and a significant loss of neurones in areas of the brain primarily associated with cognitive function and memory, such as the cerebral cortex. Classic features are neuriticplaques and neurofibrillary tangles.
Neuritic plaques are spherical structures consisting of a central core of fibrous protein, known as amyloid, that is surrounded by degenerating or dystrophic nerve endings (neurites). The amyloid protein contains a 39–42 amino acid peptide, beta-amyloid (A
Neurofibrillary tangles are found inside neurones. They are composed of paired helical filaments of hyper-phosphorylated microtubule-associated tau protein. The intracellular deposition may cause disruption of normal cell architecture, leading to cell death.
Until recently, most people received a putative diagnosis of Alzheimer’s disease or vascular dementia. However, new research has changed the subtyping of dementia considerably. According to two large studies, most people who were found to have the pathophysiological indicators of Alzheimer’s disease on post-mortem (ie, amyloid plaques and tau protein tangles) had not shown signs of dementia when alive.
In contrast, 80% of people who were found to have indicators of Alzheimer’s disease, but who also had signs of vascular damage (especially deep white matter infarcts), had shown clinical symptoms of dementia when they were alive. This suggests that most patients diagnosed with Alzheimer’s disease may have mixed Alzheimer’s and vascular dementia, pathologically.[11,12]
Other studies, involving MRI and lumbar puncture, have found that most of the amyloid deposition predates the clinical diagnosis of dementia by years, sometime seven decades, leading to the theory that for a person to show the clinical syndrome of dementia there has to have been another insult to the brain such as vascular damage or delirium.[13–15]
Box 1: Stages of severity of dementia
Mild — memory loss is prominent. Core activities of daily living, such as dressing and washing, are preserved but there are losses in higher functions of life, such as dealing with finances or operating a television remote control
Moderate — as the illness advances, cognition worsens. Core activities of daily living are more affected. Challenging behaviours can occur throughout all stages but they rise in this stage, eg, people not understanding why they are being washed or dressed, or not recognising their home or spouse and attempting to leave
Severe — apathy and dependency come to the fore. By this stage many patients are receiving 24-hour care
Vascular dementia The pathology of vascular dementia shows multifocal and diffuse lesions; damage can be caused by small strokes or injury to vessels from high blood pressure. Vascular dementia affects neuronal networks involved in cognition, behaviour, execution and memory.[16,17]
Where there is a series of strokes the condition may appear to progress in steps; decline may also appear gradual with progressive damage.
Memory may be more intact than in some other forms of dementia, depending on the area of the brain that is impaired. Emotional lability, including depression, maybe seen, as well as physical symptoms such as apraxia, slurred speech, dizziness and inability to recognise objects.
Lewy body dementia Pathologically, Lewy body dementia and dementia in Parkinson’s disease can be considered the same condition. In Lewy body dementia, the cognitive signs start first; for dementia in Parkinson’s disease, the motor symptoms of idiopathic Parkinson’s disease predate the dementia. One-third of Parkinson’s disease patients will develop dementia.
The underlying brain changes of Lewy body dementia involve clumping of the protein alpha-synuclein in the brain. These clumps are the “Lewy bodies’’ that give the condition its name. The occurrence of Lewy bodies in the cerebral cortex of demented patients was first recognised in 1961.
There are many features shared with Alzheimer’s disease. The loss of cholinergic neurones is thought to be involved in problems with cognition, whereas the loss of dopaminergic neurones in the substantia nigra is postulated to account for the degeneration of motor control.
Unlike in Alzheimer’s disease, memory impairment is not necessarily a prominent early feature of Lewy body dementia, but it will usually appear with progression of the disease. Instead, prominent early symptoms include confusion, as well as deficits in attention, executive function and visuospatial ability. These can lead to falls, visual hallucinations and other psychiatric symptoms.
There are three core diagnostic features:
- Fluctuating cognition with pronounced variation inattention and alertness
- Recurrent visual hallucinations (typically wellformed and detailed)
- Spontaneous features of Parkinsonism
Two of these should be present for a diagnosis of probable Lewy body dementia, whereas one should be present for a diagnosis of possible Lewy body dementia. Supportive features are often present, but these aloneare not sufficient for diagnosis. They include: repeated falls and syncope; transient, unexplained loss of consciousness; severe autonomic dysfunction (eg, orthostatic hypotension and urinary incontinence); non-visual hallucinations; systematised delusions; depression; and rapid eye movement sleep disorders.
Clinically, Lewy body dementia presents as a subcortical dementia with slowness of cognition. Rushing patients during testing can make them appear more impaired than they are and if given time they will often provide correct answers. Illusions are also common when the person misperceives visual cues; for example, seeing trees move in the wind could be perceived as green soldiers.
Frontotemporal dementias Frontotemporal dementias affect the front of the brain. They usually occur at an earlier age, the peak incidence being 55 to 65 years, and can present with dis inhibitive, apathetic and language effects rather than memory loss. Primary progressive aphasia is the type of dementia where outward speech decreases; in semantic dementia there are failures in understanding language.
Other dementias Alcohol does not cause a progressive dementia but it can cause cognitive damage, particularly Korsakoff ’s psychosis.
In mild cognitive impairment (described as mild cognitive disorder in ICD-10) there is subjective and objective loss of cognition, but no interference with functional ability. Mild cognitive impairment was originally suggested to be an early stage of dementia; however, it has an uncertain prognosis and can be associated with subsyndromal anxiety or depression, harmful alcohol use, concurrent medication and brain damage.
The chances of developing dementia increase with age.Except in the rare genetic forms of the illness, there is no single risk factor but rather an accumulation of factors that lead to dementia. Most risk factors are cardiovascular, because older people show mixed Alzheimer’s and vascular changes on post-mortem, and it is thought to be the latter that tips people from being asymptomatic to having clinical signs of dementia.
GeneticI n some cases, early-onset Alzheimer’s disease is caused by mutations in the APP gene and the two presenilin genes PSEN1 and PSEN2. People with any of these extremely rare mutations tend to developAlzheimer’s disease in their 30s or 40s.
For later onset Alzheimer’s disease, the gene with the most known impact on the risk of development is apolipoprotein E (APOE). There are three isoforms of this gene: APOE-e2, APOE-e3 and APOE-e4. Everyone has two copies of the APOE gene, which means that there aresix genetic combinations. Having one copy of APOE-e4increases the risk of developing dementia fourfoldcompared with the average, but having two copiesincreases it 10-fold. In contrast, APOE-e2 may be protective, and people carrying this gene are less likely to develop dementia until late in life.
Down’s syndrome People with Down’s syndrome often develop the plaques and tangles commonly seen inAlzheimer’s disease. One in three people with Down’s syndrome will show symptoms of dementia by the age of 60 years.
People with learning disabilities are also at higher risk of displaying early-onset dementia (three to four times more likely than the general population) and having arapid progression of the condition. Men with limited education may be at increased risk of developingdementia.
Hypertension The vascular dementia arm of the“systolic hypertension in Europe” (Sys-Eur) trial investigated whether antihypertensive drug treatment could reduce the incidence of dementia. The results showed that such treatment was associated with a lower incidence of dementia, suggesting that if 1,000 patients with high blood pressure were treated with antihypertensive medicines for five years, 19 cases of dementia might be prevented.
Cholesterol Elevated levels of low-density lipoprotein cholesterol have been shown to be an independent risk factor for the development of dementia with stroke. However, no association has been found between lipid levels and the risk of Alzheimer’s disease, suggesting that cholesterol might be more closely linked with dementia that has a vascular component.
Diabetes Diabetes is associated with a reduction in cerebral perfusion due to micro- and macrovascular changes, often resulting in infarctions. People with diabetes are therefore considered to have an increased risk of developing vascular dementia.
Obesity Obesity is a risk factor for cardiovascular disease and stroke, which impacts on the chances of developing dementia from vascular damage.
Depression People who experience depression in later life, or have a history of depression, are more likely to develop dementia. However, the relationship between depression and dementia remains unclear. Some researchers consider that depression is a risk factor for dementia, whereas others believe it may be an early symptom of the disease. Depressive symptoms have been shown to increase the risk of subsequent cognitive decline. Nonetheless, although depression is common in early dementia it is not a predictor of Alzheimer’s disease. High levels of cortisol might be associated with depression, and indeed stress, and might also cause neuronal death.
Alcohol Several studies have shown an increased risk of vascular dementia in patients with a history of alcohol misuse, but not all research supports this. Some studies have shown that a light to moderate consumption of alcohol could have a protective effect.[30,31] Smoking Smoking was shown to be a risk factor for dementia in one major study, whereas another did not show any association. However, the latter could be explained by the decreased life expectancy of smokers offsetting the raised prevalence of dementia with increasing age.
Aluminium The relationship between Alzheimer’s disease and aluminium is difficult to assess. Epidemiological studies were instigated in response to the observation of aluminium within plaques and tangles. Aluminium can cause abnormal phosphorylation of tau protein. Although initial studies linked aluminium toxicity with Alzheimer’s disease, the link has not been proven despite continuing investigation. Importantly, there is no evidence to suggest that aluminium exposure increases the overall risk of dementia. ExerciseExercising three times a week or more reduced the incidence of dementia from 19.7 to 13 per 1,000person years. This may be due to increased blood flow and perfusion to the neurones and improved neuronal connectivity. Brain cognitive networks studied using functional MRI show improved connectivity after six to12 months of exercise.
Delirium Delirium is common on acute wards and in intensive care settings, and diagnosis should be differentiated from dementia to ensure appropriate management. There is possibly an increased risk of developing dementia where delirium has been diagnosed, especially in older people, among whom an eightfold increase in the diagnosis of dementia after delirium has been found; this is also associated with faster cognitive decline. Reducing riskGrowing evidence suggests that brain health is closely linked to heart and blood vessel health. The risk of developing dementia appears to increase as a result of many conditions that damage the heart or blood vessels.These include high blood pressure, heart disease, stroke, diabetes and high cholesterol levels. Therefore, the prevention and treatment of modifiable risk factors will be important in the future for reducing the impact of dementia on individuals and on society.
ACKNOWLEDGEMENT This article was prepared with the help of Simon Manchip, consultant psychiatrist at Avon andWiltshire Mental Health Partnership NHS Trust, Swindon.
- G8 countries tackle dementia. Pharmaceutical Journal 2013;291:620.
- Alzheimer’s Disease International. World alzheimer report 2010: The global economic impact of dementia. September 2010. www.alz.co.uk (accessed 15 October 2013).
- Alzheimer’s Society. Dementia 2013 infographic. 2013. www.alzheimers.org.uk(accessed 15 October 2013).
- Matthews F, Aurtur A, Barnes L. A two decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: resultsof the cognitive function and ageing study I and II. Lancet 2013;382:1405–12.
- Royal College of Nursing. Dementia: Commitment to the care of people with dementiain hospital settings. January 2013. www.rcn.org.uk (accessed 15 October 2013).
- World Health Organization. International Classification of Diseases (10th revision):mental and behavioural Disorders. Geneva: World Health Organisation; 1992.
- Ballard C, Oyebode F. Psychotic symptoms in patients with dementia. International Journal of Geriatric Psychiatry 1995;10:743–52.
- Liperoti R, Pedone C, Corsonello A. Antipsychotics for the treatment of behavioural and psychological symptoms of dementia. Current Neuropharmacology 2008;6:117–24.
- National Institute for Health and Care Excellence. Dementia: Supporting people with dementia and their carers in health and social care. November 2006. www.nice.org.uk/cg42 (accessed 15 October 2013).
- Bayer TA, Wirths O, Majtenyi K, et al. Key factors in Alzheimer’s disease: b-amyloid precursor protein processing, metabolism and intraneuronal transport. Brain Pathology 2001;11:1–11.
- Peterson RC, Parisi JE, Dickson DW, et al. Neuropathologic features of amnestic mildcognitive impairment. Archives of Neurology 2006;63:665–72.
- Vinters HV. Neuropathology of amnestic mild cognitive impairment. Archives of Neurology 2006;63:645–6.
- Jack CR Jr, Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease. Brain 2010;133:3336–48.
- Cairns NJ, Ikonomovic MD, Benzinger T, et al. Absence of Pittsburgh Compound B detection of cerebral amyloid beta in a patient with clinical, cognitive and cerebrospinal fluid markers of Alzheimer disease. Archives of Neurology 2009;66:1557–62.
- Fagan AM, Mintun MA, Shah AR, et al. Cerebrospinal fluid tau and ptau181 increasewith cortical amyloid deposition in cognitively normal individuals: Implications for futureclinical trials of Alzheimer’s disease. EMBO Molecular Medicine 2009;1:371–80.
- Jellinger KA. The pathology of vascular dementia: A critical update. Journal of Alzheimer’s Disease 2008;14:107–23.
- Jellinger KA. Clinicopathological analysis of dementia disorders in the elderly: Anupdate. Journal of Alzheimer’s Disease 2006;9,61–70.
- Mark R, Griffin WS. Dementia with Lewy bodies: Definition, diagnosis, and pathogenic relationship to Alzheimer’s disease. Neuropsychiatric Disease and Treatment 2007;3:619–25.
- Okazakih H, Lipkin LE, Aronson SM. Diffuse intracytoplasmic ganglionic inclusions(Lewy type) associated with progressive dementia and quadriparesis in flexion. Journal of Neuropathology and Experimental Neurology 1961;20:237–44.
- McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the dementia with Lewy bodies (DLB) Consortium. Neurology 2005;65:1863–72.
- Alzheimer’s Society. Genetics of dementia. www.alzheimers.org.uk (accessed 15October 2013).
- McCullagh CD, Craig D, McIlroy SP, et al. Risk factors for dementia. Advances in Psychiatric Treatment 2001;7:24–31.
- Ott A, van Rossum CT, van Harskamp F, et al. Education and the incidence of dementiain a large population-based study: the Rotterdam study. Neurology 1999;52;663–6.
- Forette F, Seux M-L, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998;352:1347–51.
- Moroney JT, Tang M-X, Berglund L, et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. Journal of the American Medical Association 1999;282:254–60.
- Desmond DW, Tatemichi TK, Paik M, et al. Risk factors for cerebrovascular disease as correlates of cognitive function in a stroke-free cohort. Archives of Neurology 1993;50:162–6.
- Yaffe K, Blackwell T, Gore R, et al. Depressive symptoms and cognitive decline in nondemented elderly women: a prospective study. Archives of General Psychiatry 1999;56:425–30.
- Chen P, Ganguli M, Mulsant BH, et al. The temporal relationship between depressive symptoms and dementia: a community-based prospective study. Archives of GeneralPsychiatry 1999;56:261–6.
- Lerner AJ. Alzheimer’s disease in males: endocrine issues and prospects. Journal of Clinical Endocrinology and Metabolism 1999;84:3416–9.
- Meyer JS, Judd BW, Tawakina T, et al. Improved cognition after control of risk factors for multi-infarct dementia. Journal of the American Medical Association 1986;256:2203–9.
- Lindsay J, Hébert R, Rockwood K. The Canadian study of health and aging. Risk factors for vascular dementia. Stroke 1997;28:526–30.
- McLachlan DR, Bergeron C, Smith JE, et al. Risk for neuropathologically confirmed Alzheimer’s disease and residual aluminium in municipal drinking water employing weighted residential histories. Neurology 1996;46:401–5.
- Alzheimer’s Society. Am I at risk of developing dementia? Factsheet.www.alzheimers.org.uk (accessed 15 October 2013).
- Larson EB, Wang L, Bowen JD, et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Annals of Internal Medicine 2006;144:73–81.
- Ahlskog JE, Geda YE, Graff-Radford NR, et al. Physical exercise as a preventive or disease-modifying treatment of dementia and brain aging. Mayo Clinic Proceedings 2011;86:876–84.
- Davis DH, Muniz Terrera G, Keage H, et al. Delirium is a strong risk factor for dementia in the oldest-old: a population-based cohort study. Brain 2012;135:2809–16.